«The PEC -
Direct islet cell replacement therapy is designed to help patients with the most urgent medical need.»
«JDRF remains dedicated to accelerating the delivery of beta cell replacement therapies to the T1D community, and we commend ViaCyte in its announcement of the first patients to be implanted with the PEC -
Direct islet cell replacement therapy,» said Derek Rapp, JDRF President and Chief Executive Officer.
Not exact matches
Using
cells from cadavers, doctors have been experimentally transplanting pancreatic
islets into humans for decades, but as many as 60 percent of the transplanted
islets die immediately because they are cut off from their blood supply and are killed by an immune response due to
direct injection into the bloodstream, and those that survive the transplant usually die within several months.
Using the material and protein combination, the researchers evaluated multiple locations for implanting the
islet cell clusters, the first time such a
direct comparison of transplant sites has been made.
In addition to providing an unlimited supply of
cells for implantation, the PEC -
Direct approach has the potential to provide other advantages relative to cadaver
islet transplants such as delivering a more consistent product preparation under quality - controlled cGMP conditions, with a more straightforward and safer mode of delivery.
The Company's pluripotent stem
cell - derived
islet cell replacement therapy, the PEC -
Direct ™ product candidate, has the potential to be a breakthrough treatment for high - risk type 1 diabetes.
In addition to providing an unlimited supply of
cells for implantation, the PEC -
Direct approach has other potential advantages relative to cadaver
islet transplants such as delivering a more consistent product preparation under quality - controlled cGMP conditions, and a more straightforward and safe mode of delivery.
San Diego, August 1, 2017 — ViaCyte, Inc., a privately - held, leading regenerative medicine company, announced today that the first patients have been implanted with the PEC -
Direct ™ product candidate, a novel
islet cell replacement therapy in development as a functional cure for patients with type 1 diabetes who are at high risk for acute life - threatening complications.